Then, we evaluated whether FGF21 alone or FGF21/sTGFBR2 combination therapy improved metabolic dysfunction associated with lipodystrophy in an adipocyte-specific lamin A/C–knockout (LmnaADKO) mouse model (34). The gene discussed is FGF21; the disease is lipodystrophy.